CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer

Comment: CDK4/6 inhibitors in advanced breast cancer

Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer

Important developments in radiation oncology

Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA trials

Implementing the Breast Health Global Initiative guidelines

Guidelines for prepectoral implant-based breast reconstruction

CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer

Implementing national cancer control plans

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer

The potential of PARP inhibitors in new cancer groups and in combination with other treatments